Ultragenyx Pharmaceutical Inc.

NASDAQ:RARE  
78.42
+0.02 (+0.03%)
Products

Ultragenyx And Mereo BioPharma Announce License Agreement For Setrusumab

Published: 12/17/2020 21:41 GMT
Ultragenyx Pharmaceutical Inc. (RARE) - Ultragenyx and Mereo Biopharma Announce Collaboration and License Agreement for Setrusumab in Osteogenesis Imperfecta.
Ultragenyx Pharmaceutical Inc - Mereo Receives $50 Million Upfront and is Eligible for Milestones Up to $254 Million.
Ultragenyx Pharmaceutical Inc - Ultragenyx Leads and Funds Development to Approval.
Ultragenyx Pharmaceutical Inc - Mereo Retains Commercial Rights in Europe, Ultragenyx Commercializes in US and in Rest of World.
Ultragenyx Pharmaceutical Inc - Pediatric Phase 2/3 Study is Expected to Start in 2021.
Ultragenyx Pharmaceutical Inc - a Separate Pivotal Study is Also Being Planned for Adults With Oi.
Ultragenyx Pharmaceutical Inc - Companies Will Expand and Initially Prioritize Development of Setrusumab for Pediatric Patients With Oi.